Compare
Protagenic Therapeutics, Inc.\new vs Bio-Path Holdings, Inc. vs Pulmatrix, Inc. vs Lexaria Bioscience Corp.
| Latest fiscal year | Protagenic Therapeutics, Inc.\new PTIXRevenue covers only part of its income (partial revenue) | Bio-Path Holdings, Inc. BPTHLast annual report: year ended 2024-12-31 | Pulmatrix, Inc. PULM | Lexaria Bioscience Corp. LEXX |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2024-12-31 | 2025-12-31 | 2025-08-31 |
| Revenue | n/a | n/a | n/a | $705.9K |
| Revenue growth (YoY) | n/a | n/a | n/a | +52.0% |
| Gross margin | n/a | n/a | n/a | 99.6% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | $1.37M | -$9.89M | -$5.16M | -$11.90M |
| EPS (Diluted) | $0.59 | -$4.12 | -$1.41 | -$0.66 |
| Operating cash flow | -$2.81M | -$10.57M | -$5.43M | -$10.45M |
| Free cash flow | -$2.81M | n/a | n/a | -$10.48M |
| Cash & equivalents | n/a | n/a | $4.09M | n/a |
| Total assets | $3.65M | $3.88M | $4.14M | $4.18M |
| Total liabilities | $1.03M | $3.73M | $329.0K | $1.57M |
| Shareholders' equity | $2.62M | $154.0K | $3.81M | $2.99M |
| Return on year-end equity | 52.2% | n/m | -135.5% | -398.1% |
| Shares outstanding | 1.81M | 5.77M | 3.65M | 19.56M |
Revenue, most recent five fiscal years
| Fiscal year | Protagenic Therapeutics, Inc.\new | Bio-Path Holdings, Inc. | Pulmatrix, Inc. | Lexaria Bioscience Corp. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2018-12-31 | $7.81M Ended 2024-12-31 | $705.9K Ended 2025-08-31 |
| 1 year earlier | n/a | $37.0K Ended 2017-12-31 | $7.30M Ended 2023-12-31 | $464.3K Ended 2024-08-31 |
| 2 years earlier | n/a | $13.0K Ended 2016-12-31 | $6.07M Ended 2022-12-31 | $226.2K Ended 2023-08-31 |
| 3 years earlier | n/a | $0 Ended 2015-12-31 | $5.17M Ended 2021-12-31 | $255.4K Ended 2022-08-31 |
| 4 years earlier | n/a | $0 Ended 2014-12-31 | $12.63M Ended 2020-12-31 | $722.7K Ended 2021-08-31 |